assay
>99% (TLC)
form
powder
packaging
pkg of 1 × 1 g (880120P-1g), pkg of 1 × 200 mg (880120P-200mg), pkg of 1 × 25 mg (880120P-25mg), pkg of 1 × 500 mg (880120P-500mg)
manufacturer/tradename
Avanti Research™ - A Croda Brand
shipped in
dry ice
storage temp.
−20°C
SMILES string
[H][C@@](COP([O-])(OCCNC(OCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOC)=O)=O)(OC(CCCCCCCCCCCCCCCCC)=O)COC(CCCCCCCCCCCCCCCCC)=O.[NH4+]
InChI
1S/C133H264NO55P.H3N/c1-4-6-8-10-12-14-16-18-20-22-24-26-28-30-32-34-131(135)186-128-130(189-132(136)35-33-31-29-27-25-23-21-19-17-15-13-11-9-7-5-2)129-188-190(138,139)187-37-36-134-133(137)185-127-126-184-125-124-183-123-122-182-121-120-181-119-118-180-1
InChI key
QSWJINHFEMDVEM-OJCMNYADSA-N
General description
1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-2000 (18:0 PEG2000 PE) is conjugate, covalently attached to polyethylene glycol (PEG2000). It forms a stable micelle of 180kDa with phosphoethanolamine as hydrophobic core and hydrophilic PEG2000 as outer micelle surface.
Application
18:0 PEG2000 PE may be used in the nickel resin functionalization of quantum dots. It may also be used in liposome preparation.
Biochem/physiol Actions
1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-2000 (18:0 PEG2000 PE) is an effective drug carrier and is biocompatible. PEG stabilizes and protects the micelle from phagocytic system. The use of PEG as a conjugate with phospholipids enables improved liposome preparation and effective drug encapsulation.
Packaging
20 mL Clear Glass Screw Cap Vial (880120P-1g)
20 mL Clear Glass Screw Cap Vial (880120P-500mg)
5 mL Amber Glass Screw Cap Vial (880120P-200mg)
5 mL Amber Glass Screw Cap Vial (880120P-25mg)
Legal Information
Avanti Research is a trademark of Avanti Polar Lipids, LLC
저장 등급
11 - Combustible Solids
wgk
WGK 3
Structure and dynamics of highly PEG-ylated sterically stabilized micelles in aqueous media
Vukovic L, et al.
Journal of the American Chemical Society, 133(34), 13481-13488 (2011)
Inertial cavitation to non-invasively trigger and monitor intratumoral release of drug from intravenously delivered liposomes
Graham SM, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society, 178, 101-107 (2014)
Relationship between targeting efficacy of liposomes and the dosage of targeting antibody using surface plasmon resonance
Xiang Y, et al.
Langmuir, 31(44), 12177-12186 (2015)